Latest News and Press Releases

Applied Biologics expands strategic focus to surgical applications of XWRAP® across multiple specialties.

Applied Biologics expands its national commercial organization to support XWRAP® growth and future pipeline commercialization.

Applied Biologics completes translational study showing XWRAP® exhibits favorable wound-healing biology vs. conventional placental tissue processing.

Applied Biologics submits CAMPX Trial abstract to SAWC Fall 2026, showing XWRAP improved DFU closure rates to 30.9% vs. 17.5% for standard of care alone.

XWRAP showed statistically significant wound closure improvement vs. standard of care alone in the CAMPX RCT — 31% vs. 18% (ITT, p=0.023).

Applied Biologics presents interim CAMPX Trial data at SAWC Spring 2026, highlighting encouraging wound closure trends for XWRAP® in diabetic foot ulcers.

Applied Biologics receives FDA IND clearance for BIOxHEAL, advancing its lead biologic therapy into Phase 3 clinical trials for diabetic foot ulcers.

FRAMINGHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...

FDA approves Discovery Therapeutic Caribe's Phase 3 trial for intralesional rhEGF in severe diabetic foot ulcers.

Fiscal year-end AC5 Advanced Wound System update includes Q4 record monthly order volumes, favorable reimbursement decisions and increases in paid claims.